COST advertising at the conference

Russia-UK workshop on biomaterials for cell and drug delivery,

17th -19th September 2019, Manchester Metropolitan University, UK







Smart amphiphilic dendrimer vesicles for drug delivery

Evgeny K. Apartsin

Institute of Chemical Biology and Fundamental Medicine Novosibirsk State University Novosibirsk, Russia

Manchester- 17 Sept 2019



COST Action CA17140 is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.

By promoting scientific exchanges, technological implementation and innovative solutions, the Action will provide a timely instrument to rationalize and focus research efforts at the EU level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies.

Chair of the Action: Prof Barbara KLAJNERT-MACULEWICZ, University of Łódź, Poland **Vice Chair of the Action:** Prof Sabrina PRICL, University of Trieste, Italy E-mail: nano2clinic@biol.uni.lodz.pl



Valeria Arkhipova Dr. Olga Krasheninina Prof. Alya Venyaminova Prof. Elena Ryabchikova







Dr. Javier Sánchez-Nieves Prof. F. Javier de la Mata Prof. Rafael Gómez

Nadezhda Knauer, MD Dr. Ekaterina Pashkina



COST Action CA17140 "Cancer Nanomedicine: from the bench to the bedside"



- Gíner de los Ríos Scholarship from the University of Alcalá, Madrid, Spain
- RFBR grant No. 18-33-20109
- Grant of the President of the Russian Federation No. 2278.2019.4
- MINECO grant CTQ-2017-85224-P
- NANODENDMED-II-CM (B2017/BMD-3703)
- IMMUNOTHERCAN-CM (B2017/BMD3733)